Insider Selling: Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Sells $24,657.50 in Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Travis Alvin Thompson sold 1,750 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $24,657.50. Following the completion of the sale, the chief accounting officer now owns 34,991 shares in the company, valued at approximately $493,023.19. The trade was a 4.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Travis Alvin Thompson also recently made the following trade(s):

• On Monday, January 6th, Travis Alvin Thompson sold 2,686 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $15.00, for a total value of $40,290.00.
• On Monday, November 11th, Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $25.11, for a total transaction of $157,088.16.

Bicycle Therapeutics Stock Performance

Shares of BCYC stock opened at $14.17 on Thursday. The company has a market capitalization of $978.38 million, a PE ratio of -4.31 and a beta of 0.92. Bicycle Therapeutics plc has a 52-week low of $12.17 and a 52-week high of $28.67. The business’s fifty day moving average is $19.09 and its 200 day moving average is $21.82.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm had revenue of $2.68 million for the quarter, compared to analysts’ expectations of $6.82 million. During the same quarter last year, the firm posted ($1.26) EPS. The company’s revenue was down 50.0% compared to the same quarter last year. On average, sell-side analysts forecast that Bicycle Therapeutics plc will post -3.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Bicycle Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Natixis Advisors LLC purchased a new stake in shares of Bicycle Therapeutics during the 2nd quarter valued at $261,000. TD Asset Management Inc increased its stake in Bicycle Therapeutics by 76.7% in the second quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock valued at $1,967,000 after acquiring an additional 42,200 shares during the last quarter. Renaissance Technologies LLC raised its position in Bicycle Therapeutics by 97.2% during the second quarter. Renaissance Technologies LLC now owns 326,800 shares of the company’s stock valued at $6,614,000 after purchasing an additional 161,100 shares in the last quarter. L & S Advisors Inc lifted its stake in Bicycle Therapeutics by 16.1% during the second quarter. L & S Advisors Inc now owns 58,335 shares of the company’s stock worth $1,181,000 after purchasing an additional 8,075 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in Bicycle Therapeutics during the second quarter worth about $206,000. 86.15% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BCYC has been the topic of several research reports. B. Riley lowered their price target on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Needham & Company LLC reiterated a “buy” rating and issued a $38.00 price objective on shares of Bicycle Therapeutics in a research note on Thursday, October 31st. Stephens assumed coverage on Bicycle Therapeutics in a research report on Friday, November 8th. They set an “equal weight” rating and a $25.00 target price on the stock. JMP Securities reduced their price target on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research report on Wednesday, December 18th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $35.00 price objective on shares of Bicycle Therapeutics in a report on Friday, November 1st. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $35.25.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.